Annals of Surgical Oncology

, Volume 26, Issue 11, pp 3673–3680 | Cite as

Surgery or Radiotherapy of the Primary Tumor in T1–2 Head and Neck Squamous Cell Carcinoma with Resectable N3 Nodes: A Multicenter GETTEC Study

  • Florent Carsuzaa
  • Juliette Thariat
  • Philippe Gorphe
  • Christian Righini
  • Alain Cosmidis
  • Sébastien Thureau
  • Maximilien Roge
  • Erwan De Mones
  • Stéphanie Servagi-Vernat
  • Denis Tonnerre
  • Sylvain Morinière
  • Amaury Dugas
  • Olivier Malard
  • François Pasquier
  • Sébastien Vergez
  • Julia Salleron
  • Xavier DufourEmail author
Head and Neck Oncology



The prognosis of advanced nodal (N3) squamous cell carcinoma of the head and neck (HNSCC) is poor. We investigated whether surgery or radiotherapy of early (T1–2) primary stage HSNCC is preferable to limit the overall morbidity after upfront neck dissection (uND) for N3 disease.


This retrospective multicentric Groupe d’Étude des Tumeurs de la Tête Et du Cou study included patients undergoing uND and surgery or radiotherapy of their primary. Prognostic factors were evaluated using propensity score matching to account for biases in performing surgery depending on primary site and stage.


Of 189 T1–2, N3 HNSCC patients, 70 (37.0%) underwent uND: 42 with surgery of their primary and 28 with radiotherapy only. Radiotherapy alone was more frequent in patients with hypopharyngeal primaries. All local (N = 3) and regional (N = 10) relapses (included 2 locoregional relapses) occurred within the first 2 years. There were 16 distant metastatic failures. Five-year locoregional relapse and survival incidences were 15.7% and 66.5% and were similar regardless of the treatment of the primary. The overall morbidity rate was 65.2% and was similar after weighting by the inverse propensity score (p = 0.148). The only prognostic factor for morbidity was the radicality of the uND. Prolonged parenteral feeding was not more frequent in patients only irradiated to their primary (p = 0.118). Prolonged tracheostomy was more frequent after surgery of the primary.


In patients with T1–2, N3 HNSCC undergoing uND, radiotherapy and surgery of the primary yield similar oncological outcomes. Morbidity was related to the extent of neck dissection.



Awarded best presentation at the SCFFC 2017 and presented at the SFRO 2018 and the SFORL 2018. Accepted for oral communication at the congress of European ORL-HNS Brussels 2019. The authors acknowledge the Cooperative group of French head and neck surgeons (Groupe d’Etude des Tumeurs de la Tête et du Cou, GETTEC), and for secured encrypted collection and extraction of the database. This manuscript has been reviewed and edited by a native English speaker.


  1. 1.
    Strasser MD, Gleich LL, Miller MA, Saavedra HI, Gluckman JL. Management implications of evaluating the N2 and N3 neck after organ preservation therapy. Laryngoscope. 1999;109(11):1776–80.CrossRefPubMedGoogle Scholar
  2. 2.
    Hamoir M, Ferlito A, Schmitz S, Hanin FX, Thariat J, Weynand B, et al. The role of neck dissection in the setting of chemoradiation therapy for head and neck squamous cell carcinoma with advanced neck disease. Oral Oncol. 2012;48(3):203–10.CrossRefPubMedGoogle Scholar
  3. 3.
    Thariat J, Ang KK, Allen PK, Ahamad A, Williams MD, Myers JN, et al. Prediction of neck dissection requirement after definitive radiotherapy for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2012;82(3):e367–74.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Geoffrois L, Martin L, De Raucourt D, Sun XS, Tao Y, Maingon P, et al. Induction chemotherapy followed by cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas: results of the GORTEC 2007-02 phase III randomized trial. J Clin Oncol. 2018:JCO2017762591.Google Scholar
  5. 5.
    Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014;32(25):2735–43.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Haddad R, O’Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013;14(3):257–64.CrossRefPubMedGoogle Scholar
  7. 7.
    Mehanna H, McConkey CC, Rahman JK, Wong WL, Smith AF, Nutting C, et al. PET-NECK: a multicentre randomised phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technol Assess. 2017;21(17):1–122.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Mehanna H, Wong WL, McConkey CC, Rahman JK, Robinson M, Hartley AG, et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. N Engl J Med. 2016;374(15):1444–54.CrossRefPubMedGoogle Scholar
  9. 9.
    Rosenbaum PR. Optimal matching for observational studies. J Am Stat Assoc. 1989;84:1024–32.CrossRefGoogle Scholar
  10. 10.
    Argiris A, Stenson KM, Brockstein BE, Mittal BB, Pelzer H, Kies MS, et al. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer. Head Neck. 2004;26(5):447–55.CrossRefPubMedGoogle Scholar
  11. 11.
    Ballonoff A, Raben D, Rusthoven KE, Bassetti M, Kane M, Song JI, et al. Outcomes of patients with n3 neck nodes treated with chemoradiation. Laryngoscope. 2008;118(6):995–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Chan SW, Mukesh BN, Sizeland A. Treatment outcome of N3 nodal head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg. 2003;129(1):55–60.CrossRefPubMedGoogle Scholar
  13. 13.
    Corry J, Peters L, Fisher R, Macann A, Jackson M, McClure B, et al. N2–N3 neck nodal control without planned neck dissection for clinical/radiologic complete responders-results of Trans Tasman Radiation Oncology Group Study 98.02. Head Neck. 2008;30(6):737–42.Google Scholar
  14. 14.
    Tao Y, Auperin A, Graff P, Lapeyre M, Gregoire V, Maingon P, et al. Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: ooled analysis of two GORTEC randomized trials. Oral Oncol. 2017;71:61–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Dequanter D, Lothaire P, Awada A, Lalami Y, Hien Nguyen T, Lemort M, et al. Does clinical and radiological response predict complete tumor control in N2–N3 squamous cell head and neck cancer after non-operative management of the neck? Acta Otolaryngol. 2006;126(11):1225–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Igidbashian L, Fortin B, Guertin L, Soulieres D, Coulombe G, Belair M, et al. Outcome with neck dissection after chemoradiation for N3 head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2010;77(2):414–20.CrossRefPubMedGoogle Scholar
  17. 17.
    Karakaya E, Yetmen O, Oksuz DC, Dyker KE, Coyle C, Sen M, et al. Outcomes following chemoradiotherapy for N3 head and neck squamous cell carcinoma without a planned neck dissection. Oral Oncol. 2013;49(1):55–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Ko HC, Chen S, Wieland AM, Yu M, Baschnagel AM, Hartig GK, et al. Clinical outcomes for patients presenting with N3 head and neck squamous cell carcinoma: analysis of the National Cancer Database. Head Neck. 2017;39(11):2159–70.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Lee DJ, Cosmatos D, Marcial VA, Fu KK, Rotman M, Cooper JS, et al. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys. 1995;32(3):567–76.CrossRefPubMedGoogle Scholar
  20. 20.
    Moukarbel RV, Fung K, Venkatesan V, Franklin JH, Pavamani S, Hammond A, et al. The N3 neck: outcomes following primary chemoradiotherapy. J Otolaryngol Head Neck Surg. 2011;40(2):137–42.PubMedGoogle Scholar
  21. 21.
    Nishikawa D, Hanai N, Ozawa T, Hirakawa H, Suzuki H, Nakashima T, et al. Role of induction chemotherapy for N3 head and neck squamous cell carcinoma. Auris Nasus Larynx. 2015;42(2):150–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Soltys SG, Choi CY, Fee WE, Pinto HA, Le QT. A planned neck dissection is not necessary in all patients with N2-3 head-and-neck cancer after sequential chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2012;83(3):994–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Smyth JK, Deal AM, Huang B, Weissler M, Zanation A, Shores C. Outcomes of head and neck squamous cell carcinoma patients with N3 neck disease treated primarily with chemoradiation versus surgical resection. Laryngoscope. 2011;121(9):1881–7.PubMedGoogle Scholar
  24. 24.
    Chung MK, Son YI, Cho JK, So YK, Woo SH, Jeong HS, et al. Therapeutic options in patients with early T stage and advanced N stage of tonsillar squamous cell carcinomas. Otolaryngol Head Neck Surg. 2010;143(6):808–14.CrossRefPubMedGoogle Scholar
  25. 25.
    D’Cruz A K, Pantvaidya GH, Agarwal JP, Chaukar DA, Pathak KA, Deshpande MS, et al. Split therapy: planned neck dissection followed by definitive radiotherapy for a T1, T2 pharyngolaryngeal primary cancer with operable N2, N3 nodal metastases–a prospective study. J Surg Oncol. 2006;93(1):56–61.CrossRefPubMedGoogle Scholar
  26. 26.
    Laccourreye O, Malinvaud D, Holostenco V, Menard M, Garcia D, Bonfils P. Value and limits of non-robotic transoral oropharyngectomy for local control of T1-2 invasive squamous cell carcinoma of the tonsillar fossa. Eur Ann Otorhinolaryngol Head Neck Dis. 2015;132(3):141–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Thariat J, Hamoir M, Garrel R, Cosmidis A, Dassonville O, Janot, et al. Management of the neck in the setting of definitive chemoradiation: Is there a consensus? A GETTEC study. Ann Surg Oncol. 2012;19(7):2311–9.Google Scholar
  28. 28.
    Newman JR, Connolly TM, Illing EA, Kilgore ML, Locher JL, Carroll WR. Survival trends in hypopharyngeal cancer: a population-based review. Laryngoscope. 2015;125(3):624–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Al-Mamgani A, Meeuwis CA, van Rooij PH, Mehilal R, Basdew H, Sewnaik A, et al. Node-positive hypopharyngeal cancer treated by (chemo)radiotherapy: impact of up-front neck dissection on outcome, toxicity, and quality of life. Head Neck. 2013;35(9):1278–86.CrossRefPubMedGoogle Scholar
  30. 30.
    Elicin O, Albrecht T, Haynes AG, Bojaxhiu B, Nisa L, Caversaccio M, et al. Outcomes in advanced head and neck cancer treated with up-front neck dissection prior to (chemo)radiotherapy. Otolaryngol Head Neck Surg. 2016;154(2):300–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Machtay M, Moughan J, Farach A, Martin-O’Meara E, Galvin J, Garden AS, et al. Hypopharyngeal dose is associated with severe late toxicity in locally advanced head-and-neck cancer: an RTOG analysis. Int J Radiat Oncol Biol Phys. 2012;84(4):983–9.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008;26(21):3582–9.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Hamant C, Deneuve S, Albaret MA, Zrounba P, Breton P, Ceruse P, et al. [Smoking and alcohol cessation programs in patients with head and neck cancer]. Bull Cancer. 2018;105(11):1012–9.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Florent Carsuzaa
    • 1
  • Juliette Thariat
    • 2
  • Philippe Gorphe
    • 3
  • Christian Righini
    • 4
  • Alain Cosmidis
    • 5
  • Sébastien Thureau
    • 6
  • Maximilien Roge
    • 6
  • Erwan De Mones
    • 7
  • Stéphanie Servagi-Vernat
    • 8
  • Denis Tonnerre
    • 1
  • Sylvain Morinière
    • 9
  • Amaury Dugas
    • 10
  • Olivier Malard
    • 11
  • François Pasquier
    • 11
  • Sébastien Vergez
    • 12
  • Julia Salleron
    • 13
  • Xavier Dufour
    • 1
    Email author
  1. 1.ENT, Service ORL, Chirurgie cervico-maxillo-faciale et audiophonologieCHU de PoitiersPoitiersFrance
  2. 2.RadiotherapyCentre François Baclesse/ARCHADECaenFrance
  3. 3.Department of Head and Neck Oncology, Gustave RoussyUniversity Paris-SaclayVillejuifFrance
  4. 4.ENTCHU GrenobleLa TroncheFrance
  5. 5.ENTCHU LyonLyonFrance
  6. 6.RadiotherapyCentre Henri BecquerelRouenFrance
  7. 7.ENTCHU Bordeaux PellegrinBordeauxFrance
  8. 8.RadiotherapyCentre Jean GodinotReimsFrance
  9. 9.ENTCHU ToursToursFrance
  10. 10.ENTCHU CaenCaenFrance
  11. 11.ENTCHU NantesNantesFrance
  12. 12.ENTInstitut Universitaire du Cancer de Toulouse Oncopole – CHU de ToulouseToulouseFrance
  13. 13.Cellule Data Biostatistique, Institut de Cancérologie de LorraineUniversité de LorraineVandœuvre-Lès-NancyFrance

Personalised recommendations